Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2026 07:00 ET | Source: Denovo Biopharma

Denovo Announces Issuance of U.S. Patent of Novel Genetic Biomarker ANK3 (DGM4™) for Liafensine (DB104)

Denovo Announces Issuance of U.S. Patent of Novel Genetic Biomarker ANK3 (DGM4™) for Liafensine (DB104)
September 11, 2025 07:00 ET | Source: Denovo Biopharma

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 for Treatment-Resistant Depression Published in JAMA Psychiatry